Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ketamine Hydrochloride Clear all
Completed Phase 2 Interventional Results available

Ketamine for the Treatment of Opioid Use Disorder and Depression

NCT04177706
View directory record Official record
Conditions
Depression, Opioid-use Disorder, Opioid Abuse
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Early Phase 1 Interventional Results available

Inpatient Single Dose Interventions for Alcohol Use Disorder

NCT04562779
View directory record Official record
Conditions
Alcohol Use Disorder, Severe
Interventions
Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage
Drug · Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Completed No phase listed Observational

Exploring Sedation Types During Cataract Surgery

NCT04725747
View directory record Official record
Conditions
Vital Signs
Interventions
Midazolam/Ketamine HCl 3mg-50mg sublingual, Intravenous Sedatives with or Without Analgesia
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
55 Years to 80 Years
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Terminated Early Phase 1 Interventional

Ketamine in Veterans With Gulf War Illness

NCT04712071
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)

NCT00749203
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, PTSD, Depression, Anxiety Disorder
Interventions
Midazolam, Ketamine
Drug
Lead sponsor
Dennis Charney
Other
Eligibility
21 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

NCT05046184
View directory record Official record
Conditions
Major Depressive Disorder, Healthy Controls
Interventions
Ketamine Hydrochloride, Midazolam injection
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine

NCT03621085
View directory record Official record
Conditions
Hemorrhage, Healthy
Interventions
Ketamine Hydrochloride, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain

NCT05864053
View directory record Official record
Conditions
Pain, Neuropathic
Interventions
Ketamine, (2R,6R)-hydroxynorketamine, Saline
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Neurobiology of Suicide

NCT02543983
View directory record Official record
Conditions
Healthy Volunteers, Depression
Interventions
Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices, Magnetic Resonance Imaging scanner, 7T, Ketamine Hydrochloride
Device · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Results available

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

NCT03156504
View directory record Official record
Conditions
Major Depression, Bipolar I Disorder, Bipolar II Disorder, Unipolar Depression
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 30, 2026, 7:23 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression

NCT04011592
View directory record Official record
Conditions
Post Partum Depression
Interventions
Ketamine 0.5 mg/kg, Ketamine 0.2 mg/kg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 30, 2026, 7:23 PM EDT
Not yet recruiting Phase 4 Interventional

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts

NCT07139106
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Ketamine hydrochloride infusion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

NCT06538285
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francicso, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Withdrawn Phase 3 Interventional

Endogenous Opioid Modulation by Ketamine

NCT03051945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine Hydrochloride, Normal saline
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Sep 30, 2026, 7:23 PM EDT
Recruiting No phase listed Observational

Anesthetics and Analgesics in Children

NCT03427736
View directory record Official record
Conditions
Anesthesia, Pain
Interventions
Ketorolac Tromethamine, Hydromorphone, Ketamine, Oxycodone, Morphine
Drug
Lead sponsor
Chi Dang Hornik
Other
Eligibility
0 Years to 17 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Stanford, California • Aurora, Colorado • Wilmington, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

Continuation Ketamine in Major Depression

NCT00548964
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lithium, Ketamine
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Sep 30, 2026, 7:23 PM EDT
Suspended Phase 2 Interventional

Ketamine HCl Prolonged Release Oral Tablets for CRPS

NCT06419985
View directory record Official record
Conditions
Complex Regional Pain Syndromes
Interventions
80mg/day Ketamine HCl Prolonged Release, 160mg/day Ketamine HCl Prolonged Release
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 64 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 30, 2026, 7:23 PM EDT
Not listed Phase 3 Interventional

NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression

NCT03396601
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideation
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Hollywood, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide

NCT02133001
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

NCT04669665
View directory record Official record
Conditions
Depressive Disorder, Major, Suicidal
Interventions
SLS-002, Placebo, Standard of care, Intranasal device
Drug · Other · Device
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Orange, California • Panorama City, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 30, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketamine for Depression: An MRI Study

NCT02544607
View directory record Official record
Conditions
Depression, Anxious Depression, Major Depressive Disorder
Interventions
Ketamine, Magnetic Resonance Imaging (MRI)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 30, 2026, 7:23 PM EDT